(Q57268596)

https://api.crossref.org/works/10.1517%2F14728220802600715

Effect of ACAT inhibition on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Biomedicine. Lowering LDL--not only how low, but how long?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Human and mouse proteases: a comparative genomic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Towards third generation matrix metalloproteinase inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The proprotein convertases and their implication in sterol and/or lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Proprotein convertases [corrected] are responsible for proteolysis and inactivation of endothelial lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Hepatic proprotein convertases modulate HDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

21 January 2018

The mystery of PCSK9.

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Familial hypercholesterolaemia in Portugal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Dual regulation of the LDL receptor--some clarity and new questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Molecular biology of PCSK9: its role in LDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

New targets and emerging therapies for reducing LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Unravelling the functional significance of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The proprotein convertases are potential targets in the treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The activation and physiological functions of the proprotein convertases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Antisense apolipoprotein B therapy: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

LNA-mediated microRNA silencing in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Plasma PCSK9 levels correlate with cholesterol in men but not in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Molecular basis for LDL receptor recognition by PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Novel Robinow syndrome causing mutations in the proximal region of the frizzled-like domain of ROR2 are retained in the endoplasmic reticulum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Molecular population genetics of PCSK9: a signature of recent positive selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Of PCSK9, cholesterol homeostasis and parasitic infections: possible survival benefits of loss-of-function PCSK9 genetic polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715

Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802600715